Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Prostatic Neoplasms × Actinium × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 27 Prednisone 22 enzalutamide 15 pembrolizumab 10 Abiraterone Acetate 9 gallium 68 PSMA-11 8 Radiotherapy 8 Pluvicto 8 Leuprolide 7 Nivolumab 6 Magnetic Resonance Spectroscopy 6 Estramustine 5 Biopsy 5 orteronel 4 olaparib 4 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4 Specimen Handling 4 Radiotherapy, Intensity-Modulated 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 Cyclophosphamide 4 Carboplatin 4 tremelimumab 3 durvalumab 3 darolutamide 3 cemiplimab 3 cabazitaxel 3 bicalutamide 3 avelumab 3 abiraterone 3 Radiosurgery 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07414940 2026-02-17

ACT-RESoLUTE

University College, London

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡